Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells

Matthew Wood, Melissa Rawe, Gunnar Johansson, Shu Pang, Ryan S. Soderquist, Ami V. Patel, Sandra Nelson, William Seibel, Nancy Ratner, Yolanda Sanchez

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Malignant peripheral nerve sheath tumor (MPNST) is a life-threatening complication of neurofibromatosis type 1 (NF1). NF1 is caused by mutation in the gene encoding neurofibromin, a negative regulator of Ras signaling. There are no effective pharmacologic therapies for MPNST. To identify new therapeutic approaches targeting this dangerous malignancy, we developed assays in NF1 +/+ and NF1 -/- MPNST cell lines and in budding yeast lacking the NF1 homologue IRA2 (ira2Δ). Here, we describe UC1, a small molecule that targets NF1 -/- cell lines and ira2Δ budding yeast. By using yeast genetics, we identified NAB3 as a high-copy suppressor of UC1 sensitivity. NAB3 encodes an RNA binding protein that associates with the C-terminal domain of RNA Pol II and plays a role in the termination of nonpolyadenylated RNA transcripts. Strains with deletion of IRA2 are sensitive to genetic inactivation of NAB3, suggesting an interaction between Ras signaling and Nab3-dependent transcript termination. This work identifies a lead compound and a possible target pathway for NF1-associated MPNST, and shows a novel model system approach to identify and validate target pathways for cancer cells in which NF1 loss drives tumor formation.

Original languageEnglish (US)
Pages (from-to)1740-1750
Number of pages11
JournalMolecular cancer therapeutics
Volume10
Issue number9
DOIs
StatePublished - Sep 1 2011
Externally publishedYes

Fingerprint

Neurofibromin 1
Saccharomycetales
Neurofibromatosis 1
Neurilemmoma
Neoplasms
RNA-Binding Proteins
RNA Polymerase II
Tumor Cell Line
Yeasts
RNA

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells. / Wood, Matthew; Rawe, Melissa; Johansson, Gunnar; Pang, Shu; Soderquist, Ryan S.; Patel, Ami V.; Nelson, Sandra; Seibel, William; Ratner, Nancy; Sanchez, Yolanda.

In: Molecular cancer therapeutics, Vol. 10, No. 9, 01.09.2011, p. 1740-1750.

Research output: Contribution to journalArticle

Wood, M, Rawe, M, Johansson, G, Pang, S, Soderquist, RS, Patel, AV, Nelson, S, Seibel, W, Ratner, N & Sanchez, Y 2011, 'Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells', Molecular cancer therapeutics, vol. 10, no. 9, pp. 1740-1750. https://doi.org/10.1158/1535-7163.MCT-11-0309
Wood, Matthew ; Rawe, Melissa ; Johansson, Gunnar ; Pang, Shu ; Soderquist, Ryan S. ; Patel, Ami V. ; Nelson, Sandra ; Seibel, William ; Ratner, Nancy ; Sanchez, Yolanda. / Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells. In: Molecular cancer therapeutics. 2011 ; Vol. 10, No. 9. pp. 1740-1750.
@article{32909b5b57d743f297684621efd4f906,
title = "Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells",
abstract = "Malignant peripheral nerve sheath tumor (MPNST) is a life-threatening complication of neurofibromatosis type 1 (NF1). NF1 is caused by mutation in the gene encoding neurofibromin, a negative regulator of Ras signaling. There are no effective pharmacologic therapies for MPNST. To identify new therapeutic approaches targeting this dangerous malignancy, we developed assays in NF1 +/+ and NF1 -/- MPNST cell lines and in budding yeast lacking the NF1 homologue IRA2 (ira2Δ). Here, we describe UC1, a small molecule that targets NF1 -/- cell lines and ira2Δ budding yeast. By using yeast genetics, we identified NAB3 as a high-copy suppressor of UC1 sensitivity. NAB3 encodes an RNA binding protein that associates with the C-terminal domain of RNA Pol II and plays a role in the termination of nonpolyadenylated RNA transcripts. Strains with deletion of IRA2 are sensitive to genetic inactivation of NAB3, suggesting an interaction between Ras signaling and Nab3-dependent transcript termination. This work identifies a lead compound and a possible target pathway for NF1-associated MPNST, and shows a novel model system approach to identify and validate target pathways for cancer cells in which NF1 loss drives tumor formation.",
author = "Matthew Wood and Melissa Rawe and Gunnar Johansson and Shu Pang and Soderquist, {Ryan S.} and Patel, {Ami V.} and Sandra Nelson and William Seibel and Nancy Ratner and Yolanda Sanchez",
year = "2011",
month = "9",
day = "1",
doi = "10.1158/1535-7163.MCT-11-0309",
language = "English (US)",
volume = "10",
pages = "1740--1750",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Discovery of a small molecule targeting IRA2 deletion in budding yeast and neurofibromin loss in malignant peripheral nerve sheath tumor cells

AU - Wood, Matthew

AU - Rawe, Melissa

AU - Johansson, Gunnar

AU - Pang, Shu

AU - Soderquist, Ryan S.

AU - Patel, Ami V.

AU - Nelson, Sandra

AU - Seibel, William

AU - Ratner, Nancy

AU - Sanchez, Yolanda

PY - 2011/9/1

Y1 - 2011/9/1

N2 - Malignant peripheral nerve sheath tumor (MPNST) is a life-threatening complication of neurofibromatosis type 1 (NF1). NF1 is caused by mutation in the gene encoding neurofibromin, a negative regulator of Ras signaling. There are no effective pharmacologic therapies for MPNST. To identify new therapeutic approaches targeting this dangerous malignancy, we developed assays in NF1 +/+ and NF1 -/- MPNST cell lines and in budding yeast lacking the NF1 homologue IRA2 (ira2Δ). Here, we describe UC1, a small molecule that targets NF1 -/- cell lines and ira2Δ budding yeast. By using yeast genetics, we identified NAB3 as a high-copy suppressor of UC1 sensitivity. NAB3 encodes an RNA binding protein that associates with the C-terminal domain of RNA Pol II and plays a role in the termination of nonpolyadenylated RNA transcripts. Strains with deletion of IRA2 are sensitive to genetic inactivation of NAB3, suggesting an interaction between Ras signaling and Nab3-dependent transcript termination. This work identifies a lead compound and a possible target pathway for NF1-associated MPNST, and shows a novel model system approach to identify and validate target pathways for cancer cells in which NF1 loss drives tumor formation.

AB - Malignant peripheral nerve sheath tumor (MPNST) is a life-threatening complication of neurofibromatosis type 1 (NF1). NF1 is caused by mutation in the gene encoding neurofibromin, a negative regulator of Ras signaling. There are no effective pharmacologic therapies for MPNST. To identify new therapeutic approaches targeting this dangerous malignancy, we developed assays in NF1 +/+ and NF1 -/- MPNST cell lines and in budding yeast lacking the NF1 homologue IRA2 (ira2Δ). Here, we describe UC1, a small molecule that targets NF1 -/- cell lines and ira2Δ budding yeast. By using yeast genetics, we identified NAB3 as a high-copy suppressor of UC1 sensitivity. NAB3 encodes an RNA binding protein that associates with the C-terminal domain of RNA Pol II and plays a role in the termination of nonpolyadenylated RNA transcripts. Strains with deletion of IRA2 are sensitive to genetic inactivation of NAB3, suggesting an interaction between Ras signaling and Nab3-dependent transcript termination. This work identifies a lead compound and a possible target pathway for NF1-associated MPNST, and shows a novel model system approach to identify and validate target pathways for cancer cells in which NF1 loss drives tumor formation.

UR - http://www.scopus.com/inward/record.url?scp=80052735880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052735880&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-11-0309

DO - 10.1158/1535-7163.MCT-11-0309

M3 - Article

VL - 10

SP - 1740

EP - 1750

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 9

ER -